Results 121 to 130 of about 90,202 (264)

Discovery of a novel and potent KRAS^G12V-targeting peptide with antiproliferative activity against colorectal cancer cells. [PDF]

J Enzyme Inhib Med Chem
Zhang H, Yang S, Wang Y, Niu MM, She J.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

RETRACTION: Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells. [PDF]

Evid Based Complement Alternat Med
And Alternative Medicine EC.
europepmc   +1 more source

Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response

Cancer Science, EarlyView.
Hypericin induces autophagic AKT degradation by promoting AKT‐HSPA5 interaction in an S473 phosphorylation‐dependent manner, suppressing HCC growth. It enhances CD8+ T cell‐mediated antitumor immunity and synergizes with anti‐PD‐L1 therapy, showing favorable safety for HCC treatment. ABSTRACT Hepatocellular carcinoma (HCC) is the most prevalent primary
Sien Ma, Qianqian Xu, Mengjuan Zhu, Xianming Ge, Jian Xu, Yan Pan, Mengli Wang, Yuting Zhu, Aoxuan Xu, Hanmeng Liu, GuangHai Xiang, Weipeng Gong, Bao Zhao   +12 more
wiley   +1 more source

Plumbagin sensitizes leukemia cells to cisplatin by promoting oxidative stress, apoptosis, and DNA damage. [PDF]

Int J Med Sci
Chen YN, Lee JW, Chien TM, Yen CH, Chen BH, Chang HW.   +5 more
europepmc   +1 more source

Proteomic Analysis Reveals AMPKα‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer

Cancer Science, EarlyView.
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota, Tokiyoshi Tanegashima, Takahiko Hajime, Miho Ushijima, Shigehiro Tsukahara, Shohei Nagakawa, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto   +8 more
wiley   +1 more source

The antitumor promise of furo[2,3-<i>d</i>]pyrimidine: a 2016-2025 review. [PDF]

RSC Adv
Mansour MA, Elshafei HA, Sayed AS, Ashour AA, Hussein NE, Abdel Karim MM, Kamel FM, Elsayed NT, Ahmed MR, Seleem MT, Gomaa RM.   +10 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Evidence of Antiproliferative Activity in the Liverwort <i>Isotachis serrulata</i> from Southern Ecuador. [PDF]

Molecules
Andrade JM, Benítez Á, González-Bakker A, Cartuche L, Padrón JM, Díaz-Marrero AR, Fernandez JJ.   +6 more
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source